 |
|
|
| |
Injectable Long Acting Antiretroviral for HIV
Treatment or Prevention: The ANRS CLAPT Study
|
| |
| |
17th European AIDS Conference, November 6-9, 2019, Basel
Reported by Jules Levin
L. Slama1, R. Porcher2, C. Chakvetadze3, A. Cros1-7, F. Linard1-8, L. Gallardo1-4, J.P. Viard1, S. Carillon1-5 , J.M. Molina6 1 : Infectious Diseases Unit, Hotel Dieu Hospital, AP-HP , Universite Paris Centre, France ; 2 : Centre de Recherche epidemiologie et Statistiques , Universite de Paris (CRESS-UMR1153) ; 3 : Infectious Diseases Unit, Melun-Senart Hospital, Melun, France ; 4 : SOPHIAPOL, Paris Nanterre University, Nanterre, France 5 : CEPED, Paris Descartes University, IRD, Paris, France ; 6 : Infectious Diseases Unit, Saint Louis , APHP, Universite Paris Diderot, France ; 7 : COREVIH Ile de France Sud, Creteil, France; 8 : Infectious Diseases Unit, Tenon Hospital, AP-HP, Universite Paris Sorbonne, France
Murray M. et al, HIV Res Clin. Pract., 2019; Murray M, ATLAS, IAS, July 2019, Mexico; Murray M. et al, IAS, MOPEB258, IAS July 2019; Murray et al, HIV Clinical Trials, 2018; Margolis D. et al, Lancet 2017; Markowitz et al, The Lancet HIV, 2017; Mc Gowan I. et al, The Lancet HIV, 2016; Andrews C. D. et al, Current Opinion in HIV and AIDS, 2015; Boffito M. et al, Drugs 2014; Meyers K. et al, PLoS ONE, 2014.
|
| |
|
|
|
|
|
